Pharmacotherapy Rounds for Tampa General Hospital

Team of doctors during meeting in modern clinic

Program Details

  • Intended Audience:  Pharmacists interested associated with the Tampa General Residency Program
  • Universal Activity Number: 0012-0000-23-019-L01-P
  • Contact Hours: 1.0 General hours of ACPE continuing education for pharmacists
  • Program Fees: Complimentary for pharmacists associated with the Tampa General Residency Program
  • UAN Release Date: 07/01/2023
  • UAN Expiration Date: 06/30/2024
  • Activity Type: Knowledge
  • Program Support: No outside financial support was provided.


At the completion of this activity, the participant will be able to:

  • Review relevant epidemiology, pathophysiology, and etiology of disease states encountered by pharmacists at a tertiary care health system.
  • Discuss the pharmacology, pharmacokinetics, and literature of pertinent medications used as standard of care for common disease states seen in the tertiary care setting.
  • Summarize published literature regarding an area of clinical controversy or developing research for common disease states encountered in a tertiary care health system.
  • Compare and contrast the presented evidence with current practices at the tertiary care health system and identify opportunities for changes to practice based on relevant or new evidence.

Requirements for Successful Course Completion

Attendance at the RSS Grand Rounds presentation and submit an evaluation within 15 days of the presentation.

Schedule of Activities

TitlePresenterPresentation Date
Alternative Maintenance ImmunosuppressionElise Heiman Pharm.D.07/26/2022
Don’t be a “Harmacist”: Fluid Stewardship EditioBrittany Tyree Pharm.D.08/09/2022
Continuous Glucose MonitoringChandler Wilson
Don’t Get A-HEAD of Yourself: Andexanet alfa Versus 4 Factor Prothrombin Complex Concentrate for Factor Xa Inhibitor-Related Intracranial HemorrhageHeather Schucker Pharm.D.
Phenobarbital in Alcohol WithdrawalJaleesa DeKilder Pharm.D.
What is One to Do(ac)? Preventing Stroke in Patients with Hemophilia and Atrial FibrillationTasha Butler Pharm.D.10/25/2022
Anticoagulation in Solid Organ TransplantAysia Johnson Pharm.D.
You’re Not The Only One Who’s Hangry: Nutrition in Critically Ill PatientsAustin Burnette Pharm.D.
Review of Stem Cell Transplantation & Graft-Versus-Host Disease ManagementKylie Paul Pharm .D.
The Organ(ism) You Didn’t Know You Were Getting: Donor-Derived Infections in Solid Organ TransplantLizbeth Haker Pharm .D.
Feeling Rusty? Cleaning Up Iron ControversiesJaleesa DeKilder Pharm .D.
Symptom Free? Let it Be! When to Treat Asymptomatic BacteriuriaTasha Butler Pharm .D.2/28/2023
Let’s Get Serious About C. aurisAysia Johnson Pharm.D.
Still Alive But I’m Barely Breathing: RSI Controversies and Considerations Austin Burnette Pharm .D.
One CYP at a Time: CYP2C19 and P2Y12 Inhibitor Selection in StrokeKylie Paul Pharm.D.
PGY1 Research Grand Rounds (Lizbeth Haker, Aysia Johnson, Jaleesa DeKilder)
PGY1 Research Grand Rounds (Kylie Paul, Austin Burnette, Tasha Butler)
Lizbeth Haker Pharm.D.
PGY2 Research Grand Rounds (Elise Heiman, Brittany Tyree, Chandler Wilson, Heather Schucker)
Breaking the Mold: Emerging Fungal Infections in Solid Organ Transplant Recipients.Elise Heiman Pharm .D.6/14/2023
Blast from the RAAS:
The Role of RAAS in Vasodilatory Shock
Nicolas Tran Pharm.D.07/25/2023
Can't Live, Can't Breath Without AIR Updates in Asthma ManagementTasha Butler Pharm.D.08/18/2023
Take some PICS: Considerations and Proposed Treatments for a Novel Disease StateAustin Burnette Pharm.D.09/5/2023
More Morphine, More Problems? Morphine in Acute Coronary SyndromesEmily Montgomery Pharm.D.9/12/2023
And At Last, I “C” The Light
Organ Transplantation of Hepatitis C Virus (HCV) Positive
Donors to HCV Negative Recipients
Cody Tong Pharm.D.9/26/2023
Corticosteroids in Septic Shock: Who, When, and How to Treat?
Luke Posgai Pharm.D.10/10/2023
Immune Checkpoint Inhibitors and Immune-Related Adverse Events
Alexa Kupper Pharm.D.10/24/2023
Driving the Future of Cancer Treatment: Overview of CAR T-Cell Therapy
Haneen Ottallah Pharm.D.10/31/2023
“Triple Threat?” Updates in the use of Triple Therapy After Percutaneous Coronary Intervention
Shannon Komisarchik Pharm.D.11/7/2023
The skinny on weight loss: updates inobesity management
Savannah Nelson Pharm.D.11/14/2023
Seize the Moment: Updates in the Treatment of Refractory Status Epilepticus
Stephanie Toole Pharm.D.11/28/2023
What's New in Code Blue: Updates in Cardiac ArrestLuke Posgai Pharm.D.1/9/2024
Let’s Make the Switch: Oral Antibiotics in
Systemic Infections
Alexa Kupper Pharm.D.1/23/2024
"Assistance with Resistance: IDSA 2023 Guidance on the Treatment of Antimicrobial Resistant Gram (-) Infections"
Karl Ramos Pharm.D.1/24/2024
Management of hyperglycemic crises: ​
keep calm and put insulin on
Savannah Nelson Pharm.D.2/6/2024
A Wake-Up Call onPharmacotherapy Considerations in Sleep DisordersShannon Komisarchik Pharm.D.2/27/2024
Going Viral: Novel Therapies in Cytomegalovirus Management in Solid Organ Transplant
Haneen Ottallah Pharm.D.3/26/2024
I've GAHT to Clear This Up: Gender Affirming Hormone Therapy and Associated Pharmacologic ConsiderationsStephanie Toole Pharm.D.4/9/2024
Gone with the Weight:Weight Loss Pharmacotherapy in Solid Organ TransplantMinh Tong Pharm.D.5/20/2024

Disclosure Statement

The above speakers and respective reviewers and planning committee members have disclosed that he/she has no relevant financial disclosures. No one else in a position to control content has any financial relationships to disclose.

Additional Resources

Please review the resources below before registering for the course.


The University of Florida College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.